Program
Anti-DLL3 Antibody-drug Conjugate IDE849
Also written as “IDE849” and “SHR-4849”.
In Jiangsu HengRui Medicine’s pipeline, DLL3 ADC
. Its studies are mostly in Small Cell Lung Carcinoma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| IDEAYA Biosciencesits history only | 11 open or running | phase 2since Sep 11, 2025 | Sep 11, 2025 | Jul 2029phase 2 · NCT07174583 |
| Jiangsu HengRui Medicineits history only | 11 open or running | phase 1since May 30, 2024 | May 30, 2024 | Dec 2026phase 1 · NCT06443489 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-4849
, phase 2, as of Jul 31, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 30, 2024First study: phase 1 study in Advanced Solid TumorsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT06443489 · 80 planned · China
- Sep 11, 2025IDEAYA Biosciences’ first study: phase 2 study in Small Cell Lung CarcinomaNew to IDEAYA BiosciencesIDEAYA Biosciences · NCT07174583 · 262 planned · United States
Ahead
- Dec 2026Primary completion: phase 1 study in Advanced Solid TumorsJiangsu HengRui Medicine · NCT06443489
- Jul 2029Primary completion: phase 2 study in Small Cell Lung CarcinomaIDEAYA Biosciences · NCT07174583
TargetBeta
“DLL3 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) conjugated, via a cleavable linker, to a DNA topoisomerase I inhibitor (TOP1i), with potential antineoplastic activ…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) ”NCIt, by rule
Other programs on DLL3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tarlatamabrule | Amgen | phase 3 | 13 |
| Alveltamigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 11 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| Zocilurtatug Pelitecanrule | Zai Lab | phase 3 | 6 |
| Anti-DLL3 Antibody-drug Conjugate BL-M14D1 | Sichuan Biokin Pharmaceutical | phase 3 | 4 |
| gocatamig | Merck | phase 3 | 4 |
| Autologous Anti-DLL3 CAR-T Cells DJI136 | Novartis | phase 2 | 2 |
| SHR-7787 | Jiangsu HengRui Medicine | phase 2 | 1 |
| Anti-DLL3 Antibody-drug Conjugate FZ-AD005rule | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | phase 1 | 2 |
| clesitamig | Hoffmann-La Roche | phase 1 | 2 |
| Actinium Ac 225-ABD147rule | abdera-therapeutics-inc | phase 1 | 1 |
| Indium In 111-ETN029 | Novartis | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07174583Small Cell Lung Carcinoma · United States | 2 | Recruiting | IDEAYA Biosciences | Jul 2029 | 262 |
| NCT06443489Advanced Solid Tumors · China | 1 | Recruiting | Jiangsu HengRui Medicine | Dec 2026 | 80 |
How it is read
Names in the registry
- “IDE849”, 1 entry
- “SHR-4849”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.